Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer

2012 ◽  
Vol 134 (2) ◽  
pp. 561-567 ◽  
Author(s):  
Tobias J. Grob ◽  
Uwe Heilenkötter ◽  
Stefan Geist ◽  
Peter Paluchowski ◽  
Christian Wilke ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Predictive Markers ◽  
Oncogenic Mutations

scholarly journals Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer

Cancers ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2978
Author(s):  
Chia-Jung Li ◽  
Yen-Dun Tony Tzeng ◽  
Yi-Han Chiu ◽  
Hung-Yu Lin ◽  
Ming-Feng Hou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
High Efficiency ◽  
Early Recurrence ◽  
New Developments ◽  
Great Progress ◽  
Low Toxicity ◽  
Made In

Triple negative breast cancer (TNBC) is a heterogeneous tumor characterized by early recurrence, high invasion, and poor prognosis. Currently, its treatment includes chemotherapy, which shows a suboptimal efficacy. However, with the increasing studies on TNBC subtypes and tumor molecular biology, great progress has been made in targeted therapy for TNBC. The new developments in the treatment of breast cancer include targeted therapy, which has the advantages of accurate positioning, high efficiency, and low toxicity, as compared to surgery, radiotherapy, and chemotherapy. Given its importance as cancer treatment, we review the latest research on the subtypes of TNBC and relevant targeted therapies.

scholarly journals Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer

2020 ◽  
Vol 39 (1) ◽  
Author(s):  
Simona Camorani ◽  
Margherita Passariello ◽  
Lisa Agnello ◽  
Silvia Esposito ◽  
Francesca Collina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Triple Negative Breast Cancer ◽  
Immune Checkpoint ◽  
Triple Negative ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade

Acid-labile polysaccharide prodrug via lapatinib-sensitizing effect substantially prevented metastasis and postoperative recurrence of triple-negative breast cancer

Nanoscale ◽  
2020 ◽  
Vol 12 (25) ◽  
pp. 13567-13581 ◽  
Author(s):  
Junhui Sui ◽  
Mingda Zhao ◽  
Yuedi Yang ◽  
Zhihao Guo ◽  
Mengcheng Ma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Triple Negative Breast Cancer ◽  
Molecular Targeted Therapy ◽  
Triple Negative ◽  
Postoperative Recurrence ◽  
Sensitizing Effect ◽  
Acid Labile

Co-delivery of lapatinib and Dox by polysaccharide prodrug prevented metastasis and recurrence of triple-negative breast cancer (TNBC) that is usually insensitive to endocrine and molecular targeted therapy.

Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer

2019 ◽  
Vol 19 (8) ◽  
pp. 673-679 ◽  
Author(s):  
Jennifer Weiss ◽  
Ashley Glode ◽  
Wells A. Messersmith ◽  
Jennifer Diamond
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative

scholarly journals Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer

2010 ◽  
Vol 16 (19) ◽  
pp. 4702-4710 ◽  
Author(s):  
Carey K. Anders ◽  
Eric P. Winer ◽  
James M. Ford ◽  
Rebecca Dent ◽  
Daniel P. Silver ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative

Protein activation mapping and exploratory predictive markers for pCR in triple-negative breast cancer patients treated with neratinib in the I-SPY 2 TRIAL.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 1085-1085 ◽  
Author(s):  
Julia Dianne Wulfkuhle ◽  
Christina Yau ◽  
Denise M Wolf ◽  
Rosa Isela Gallagher ◽  
Jianghong Deng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Predictive Markers ◽  
Breast Cancer Patients ◽  
Protein Activation ◽  
Activation Mapping
Sign in / Sign up

Export Citation Format

Share Document